A multiparticulate controlled release selective serotonin reuptake
inhibitor (SSRI) formulation for oral administration comprises particles
of said SSRI or a pharmaceutically acceptable salt thereof coated with
rate-controlling polymer which allows controlled release of said SSRI,
over a period of not less than about 12 hours following oral
administration. The formulation, which contains for example fluvoxamine
or a pharmaceutically acceptable salt thereof, is suitable for once or
twice daily administration. The formulation can comprise a blend of two
or more populations of particles, pellets or mini-tablets having
different in vitro and/or in vivo release characteristics.